Rebound of COVID-19 Symptoms Rare After Nirmatrelvir/Ritonavir Treatment

THURSDAY, June 16, 2022 (HealthDay News) -- Few patients experience rebound of COVID-19 symptoms after nirmatrelvir/ritonavir (NM/R) treatment, according to research published online June 14 in Clinical Infectious Diseases.
Nischal Ranganath, M.D., Ph.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective review among patients who received NM/R treatment for mild-to-moderate severe acute respiratory syndrome coronavirus 2. Data were included for 483 patients (median age, 63 years) who had a high risk for severe disease progression. Overall, 93 percent of the patients were fully vaccinated.
The researchers found that four of the patients (0.8 percent) experienced symptom rebound, defined as recurrence of COVID-19 symptoms following successful completion of five days of NM/R therapy, at a median of nine days after NM/R treatment. All four were fully vaccinated. None of the patients required hospitalization, and all improved without further treatment.
"Rebound after NM/R treatment is uncommon in our population of high-risk, but mostly nonimmunocompromised [patients]," the authors write. "Among the patients who developed rebound of symptoms after NM/R treatment, the clinical presentation was mild and did not require COVID-19 directed therapies."
Abstract/Full Text (subscription or payment may be required)
Related Posts
FDA Questions Strength of Johnson & Johnson Booster Shot Data
WEDNESDAY, Oct. 13, 2021 (HealthDay News) -- In a development that could mean...
La vacuna contra la COVID es segura para unos niños que tuvieron una complicación rara de la COVID
MARTES, 3 de enero de 2023 (HealthDay News) -- Es seguro que los niños reciban...
Hormone Therapy Not Linked to Lung Cancer in Postmenopausal Women
FRIDAY, March 17, 2023 (HealthDay News) -- For postmenopausal women, hormone...
No hay señales de que una COVID leve en el embarazo pueda dañar al cerebro infantil
MIÉRCOLES, 12 de abril de 2023 (HealthDay News) -- Molly E. contrajo la COVID el...